SALT LAKE CITY, USA, December 20, 2017 -- LSK BioPharma (LSKB, Company) has enrolled the first US and European patients in its ongoing, multinational Phase 3 ANGEL Study; a pivotal study assessing the safety and efficacy of apatinib in patients with advanced or metastatic gastric
SALT LAKE CITY, USA, December 10, 2017 -- LSK BioPharma (LSKB, Company) announced a new initiative to study the safety and efficacy of cancer therapies combining apatinib with immunotherapy. The first clinical study, designated LSK-AM107, will take place at the Cancer Center of Southern California
Responsibilities and Duties Essential Duties & Responsibilities: Assist protocol, IB and CRF development Provide monitoring guidance Plan and assist study start-up activities such as the creation of Site Initiation Presentations, CRF Completion Guidelines and various study tracking and management documents Perform pre-site selection, site initiation, interim,
Position Summary: This position functions as a Clinical Project Manager for global late stage clinical trials within LSK BioPharma (South San Francisco) or within LSK Global CRO (Seoul) as the relevant study/project requires. The Global Clinical Trials Manager (GCTM) works primarily with CRO and other
SALT LAKE CITY, USA, June 19 2017 -- LSK BioPharma (LSKB, Company) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to apatinib for the treatment of gastric cancer. Apatinib, which has been approved and is marketed in China for patients with
SALT LAKE CITY, USA, June 1 2017 -- LSK Biopharma (LSKB Company) will be attending the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA from June 2-6. The Company will be meeting with leading oncologists and key opinion leaders from across the
SALT LAKE CITY, USA, May 16, 2017 – LSK BioPharma (LSKB, Company) announced today that it has started Site Initiation Visits (SIVs) for clinical sites in the United States for its global apatinib phase 3 gastric cancer trial. The Company has already initiated sites in
SALT LAKE CITY, USA, May 8, 2017 – LSK BioPharma (LSKB, Company) announced today that it has received approval from the Korean Ministry of Food and Drug Safety (MFDS) to initiate a phase 2 clinical trial of apatinib, the Company’s proprietary angiogenesis inhibitor, in colorectal
SALT LAKE CITY, USA, March 13, 2017 – LSK BioPharma (LSKB, Company) announced today enrollment of the first patient in a global, multicenter phase 3 trial to evaluate apatinib in patients with advanced or metastatic gastric cancer. This first patient was enrolled at ASAN Medical Center
SALT LAKE CITY, USA, March 1, 2017 – LSK BioPharma (LSKB, Company) today announced that it has received notification that the European Commission has designated apatinib as an orphan medicinal product for the treatment of gastric cancer in the European Union. Further to the development
